Tag: GlobeNewswire

Presentations will feature encore Phase 1 data highlighting the mechanism of action, redosing potential, and early C-peptide response associated with SAB-142, a fully human multi-specific ATG for Stage 3 type 1 diabetes

MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) being held October 9-11, 2026 in Philadelphia, PA. Presentations will include encore Phase 1 data for SAB-142, a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of Stage 3 T1D.

“We are proud to sponsor and participate in the inaugural Breakthrough T1D Clinical & Research Congress, an important forum bringing together researchers, clinicians, industry leaders, and advocates focused on changing the future of type 1 diabetes,” said Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO. “Our presentations will feature available safety and efficacy data for SAB-142 and provide information on the SAFEGUARD and PRISE-hATG studies evaluating SAB-142 as a potential immunotherapy across the T1D disease continuum. Our collaboration with Breakthrough T1D reflects a shared commitment to advancing innovative approaches that move beyond exogenous insulin administration and toward preserving organic endogenous insulin production.”

Oral Presentations at CRC 2026:

Title: Save All Beta Cells: Sustained Autoimmune Balance with SAB-142 Induction and Maintenance Dosing
Session: Exhibition Spotlight Presentation (Supported by SAB BIO)
Presenter: Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO; Christoph Bausch, PhD, MBA, Chief Operating Officer, SAB BIO
Presentation Date and Time: Saturday, October 10, 2026, 1:10 – 1:30 PM EDT
Location: Exhibition Area, Pennsylvania Convention Center, Philadelphia, PA

Title: Mechanism of action of SAB-142 and responsive C-peptide signal in adult patients with T1D > 100 days post diagnosis 
Session: Orals 07: Disease Modifying Therapies
Presenter: William Quinn, PhD, Executive Director, Immunology, SAB BIO
Presentation Date and Time: Saturday, October 10, 2026, 2:50 – 3:00 PM EDT
Location: Hall 103, Pennsylvania Convention Center, Philadelphia, PA

ePoster Presentations at CRC 2026 (available throughout conference):

Title: Tracking multiplicity: clinical pharmacokinetic assay for SAB-142, a multi-target therapeutic for T1D (#435)
Author: Eric Sandhurst, PhD, Director, Program Management, SAB BIO

Title: SAB-142, a fully human anti-thymocyte globulin, can be safely redosed, is not immunogenic, and has predictable PK/PD profiles in healthy volunteers  (#499)
Author: William Quinn, PhD, Executive Director, Immunology, SAB BIO

Title: Profiling the binding specificities of SAB-142, a fully human anti-thymocyte globulin, against T-cell surface proteins (#428)
Author: Diane Maher, RN, PhD, Director, Program Management, SAB BIO

The presentations will be made available in the Presentations section of the Company’s website afterwards and will remain accessible following the conference.

About SAB-142
SAB-142 is a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new- or recent-onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of “bad acting” T-lymphocytes. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.

Forward-Looking Statements
Certain statements made in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company’s T1D program and other discovery programs.

These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

CONTACTS

Investor Relations:
Christine Ryan
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

SARASOTA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (Nasdaq: ROP) announced that its financial results for the third quarter of 2026, ended September 30, 2026, will be released before the market opens on Thursday, October 22, 2026. A conference call to discuss these results has been scheduled for 8:00 AM ET on Thursday, October 22, 2026. The call can be accessed via webcast or by dialing +1 800-836-8184 (US/Canada) or +1 646-357-8785, using conference call ID 80101. Webcast information and conference call materials will be made available in the Investors section of Roper’s website prior to the start of the call.

About Roper Technologies

Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company’s website at www.ropertech.com.

Contact information:
Investor Relations
941-556-2601
investor-relations@ropertech.com

Company to engage clinicians across three key growth markets and highlight the Aquadex SmartFlow® system for precise fluid management

MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced its participation in four leading medical conferences in October spanning pediatrics, critical care, and heart failure. Across the events, Nuwellis will engage directly with clinicians on the challenge of fluid overload and the role of its Aquadex SmartFlow^® system in providing precise, controlled fluid removal for patients who require individualized fluid management.

“Pediatrics, critical care, and heart failure are the three key growth markets for Nuwellis, and fluid overload is a common and complex challenge across each of these patient populations,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “By engaging clinicians and specialists at leading meetings across all three markets, we are advancing our commercial strategy while increasing awareness of Aquadex and its ability to provide precise, adjustable fluid removal when conventional approaches may be insufficient. These conferences give us an important opportunity to deepen relationships with the specialists caring for patients who can benefit from more individualized fluid management.”

Pediatric Paracorporeal and Extracorporeal Therapies Summit (PPETS)
October 6-8 | Houston | Texas Children’s Hospital
PPETS brings together pediatric specialists focused on extracorporeal therapies and critically ill children.
For more information, visit the event’s website.

2026 Society of Thoracic Surgeons (STS) Perioperative & Critical Care Conference
October 9-10 | Baltimore | Hyatt Regency Baltimore Inner Harbor
The STS Perioperative & Critical Care Conference convenes cardiovascular and thoracic critical care teams managing complex patients, including those facing heart failure, acute kidney injury, and volume management challenges.
For more information, visit the event’s website.

Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026
October 9-12 | Phoenix | Phoenix Convention Center
Nuwellis’ Booth at the HFSA Devices Meeting on October 9: 204
The HFSA Annual Scientific Meeting brings together the multidisciplinary heart failure community across advanced, hospitalized, and chronic heart failure care.
For more information, visit the event’s website.

American Society of Nephrology’s (ASN) Kidney Week 2026
October 21-25 | Denver | Colorado Convention Center
Nuwellis’ Booth: 391
Kidney Week 2026 is ASN’s annual meeting bringing together over 12,000 kidney professionals to latest treatments and advancements in and related to the field, including across critical care nephrology, pediatric care, and heart failure.
For more information, visit the event’s website.

About Aquadex
The Aquadex SmartFlow System is currently indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism 

Expands intellectual property portfolio supporting Akari’s novel payload and ADC platform

TAMPA, Fla. and LONDON, Oct. 01, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of PCT/US2026/45955, expanding the Company’s growing intellectual property portfolio around its novel splicing-modulating payload, PH1 and PH1-based ADCs.

Alternative splicing enables cells to generate different proteins from a single gene. Cancer cells can exploit this process to produce protein variants called ‘isoforms’ that support tumor growth, proliferation and survival and promote resistance to therapy. This PCT filing expands Akari’s current patent portfolio relating to its proprietary Thailanstatin payload ADCs and the payload’s ability to disrupt alternatively spliced protein isoforms that many cancers use to survive, proliferate and spread. Accordingly, Akari’s payload PH1 uses a differentiated approach compared with traditional ADC payloads that primarily rely on tubulin inhibition (i.e., vedotin) or DNA damage as (i.e., topoisomerase I Inhibitors) mechanisms of action.

The new PCT application includes claims relating to PH1’s modulation of alternative splicing involving multiple genes associated with tumor progression, including pathways involved in:

• Inhibiting Angiogenesis: PH1 altered VEGF-A splicing, shifting cancer cells from a VEGF-A isoform with the ability to supply tumors with blood vessels bringing in nutrients and oxygen (pro-angiogenic) toward the VEGF-165b isoform that prevented blood vessel recruitment to tumors (anti-angiogenic). This switch may disrupt the ability of tumors to recruit the blood vessels necessary to support their growth and spread.
• Facilitating programmed cell death of the tumor: Cancer cells produce soluble versions of the death receptor FAS to prevent immune cells expressing the FAS ligand from recognizing the cancer cell and killing it. PH1 altered the splicing of FAS to a version that would be anchored on cell surfaces (transmembrane isoform) making the cancer cells susceptible to immune cell-mediated cell death.
• Disrupting hormone and oncogenic signaling in prostate cancer: In prostate cancer cells, PH1 demonstrated reductions in both wild-type androgen receptor (WT-AR) and the oncogenic splice variant AR-V7. WT-AR plays an important role in hormone-dependent prostate cancer, while AR-V7 is a signaling oncogene that drives tumor growth in metastatic castration-resistant prostate cancer (after hormone ablation therapy fails).

Together, these collective findings further demonstrate the versatility of PH1’s mechanism of action and its potential to disrupt different alternative splicing pathways that different cancers rely upon for survival, growth and metastasis.

Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, commented, “This PCT filing represents another important expansion of our intellectual property portfolio and further demonstrates the differentiated potential of PH1 as a novel ADC payload with unique properties vs. current ADC payloads. These claims illustrate PH1’s potential to impact multiple fundamental mechanisms that cancer tumors use to survive and spread, including angiogenesis, oncogene signaling and avoiding programmed cell death. We believe the breadth of this biology further supports the potential of PH1 as a platform payload for the development of differentiated ADCs across multiple tumor targets and cancer types. As we continue to expand our understanding of PH1, we are building an increasingly robust intellectual property foundation for our novel PH1 payload and ADC portfolio.”

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, AR-V7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the potential characteristics and therapeutic applications of PH1 and PH1-based ADCs, the ability of the Company to advance its product candidates for the treatment of cancer and the timing of a filing of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com 

New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ^® (SCD-PED) therapy

Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy

DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced that effective today, October 1, 2026, new ICD-10-PCS codes are available to enable administrative, billing, and statistical reporting for the use of SeaStar Medical’s SCD therapy in patients with AKI requiring renal replacement therapy (RRT) in the inpatient hospital setting.

“Availability of these unique ICD-10-PCS codes represents a significant milestone for our company and the clinical community,” stated Tim Varacek, Senior Vice President of Commercial and Business Operations of SeaStar Medical. “This will simplify the hospital coding process, and importantly, support our mission to broaden access to QUELIMMUNE therapy for children with AKI who are facing permanent organ damage and loss of life. The procedure codes are broadly indicated for the treatment of all patients with AKI who require RRT and we expect these designations will enable a streamlined path for the adoption of our SCD therapy for adult patients with AKI, if approved.”

The newly assigned ICD-10-PCS codes include:

• 5A1D701 – Urinary Filtration, Intermittent (<6 hours), Selective Cytopheresis
• 5A1D801 – Urinary Filtration, Prolonged Intermittent (6–18 hours), Selective Cytopheresis
• 5A1D901 – Urinary Filtration, Continuous (>18 hours), Selective Cytopheresis

Healthcare organizations may refer to SeaStar Medical’s Payer Reimbursement Guide for assistance in implementing the use of these billing codes into their existing documentation.

A PCS code refers to the ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) developed and maintained by the Centers for Medicare & Medicaid Services (CMS) specifically for use in United States hospitals to report inpatient procedures for billing, data tracking, and reimbursement purposes. The new codes provide hospitals with a clear, specific mechanism to document and seek payment when using QUELIMMUNE, addressing previous coding limitations that could have hindered broader adoption.

About QUELIMMUNE

The QUELIMMUNE^® (SCD-PED) therapy is being commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more who are on antibiotics and being treated in the ICU with RRT. It was approved in February 2024 under a Humanitarian Device Exemption application.

Data from two clinical trials of the QUELIMMUNE therapy, published in Kidney Medicine, showed a 77% survival rate in patient treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data in this patient population. No dialysis was required for survivors, and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge. In February 2026, data published in the prestigious, peer-reviewed journal, Pediatric Nephrology, highlighted the early experience from the QUELIMMUNE SAVE Registry, a post-approval surveillance registry, evaluating the role of the QUELIMMUNE therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring renal replacement therapy. Observations from the first 21 pediatric patients with AKI and sepsis requiring renal replacement therapy showed no device-related adverse events or infections and no reports of immunosuppressive effects by the device. In addition, preliminary outcomes analyses show a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90. These new data are on track to validate an observed 50% reduction in patient mortality at 60 days compared to historical data, similar to what was observed in the registration study reported in Kidney Medicine.

The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy and has broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.

About the SeaStar Medical Selective Cytopheretic Device (SCD) Therapy

The SCD therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy is designed for broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing continuous RRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future continuous RRT, including dialysis, and prevent loss of life.  

About NEUTRALIZE-AKI Pivotal Trial

The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving continuous RRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to continuous RRT as the standard of care, compared with the control group receiving only continuous RRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome. 

About Acute Kidney Injury (AKI) and Hyperinflammation 

AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as severe infections or other septic conditions, severe trauma, surgery, and organ failures. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to ICD-10-PCS codes are expected to take effect; anticipated expanded access to QUELIMMUNE as a result of the ICD-10-PCS codes; the total addressable market for the SCD applications; the ability of SeaStar Medical to gain market share and generate; broadening QUELIMMUNE adoption by the addition of top-ranked children’s medical centers; the amount and timing of future QUELIMMUNE commercial sales; commercial acceptance of QUELIMMUNE; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. 

Contact:  
IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.

MONTREAL, Oct. 01, 2026 (GLOBE NEWSWIRE) — WSP Global Inc. (TSX: WSP) (“WSP”), one of the world’s leading engineering, science and infrastructure solutions firms, has entered into an agreement to acquire GCM Corpo Inc. (“GCM Corpo”), a Canadian provider of engineering consulting and specialist services for the energy and industrial sectors.

With a presence in Québec, Western and Atlantic Canada, GCM Corpo is home to approximately 600 professionals and serves clients in a broad range of end markets, including energy, industrial, and mining and metals.

The proposed acquisition of GCM Corpo supports several priority growth areas aligned with WSP’s 2025-2027 Global Strategic Action Plan. It will expand WSP’s platform in Canada by growing its core engineering consulting business and broadening access to clients in the energy and industrial sectors, including original equipment manufacturers. The proposed transaction will also strengthen WSP’s capabilities in process engineering, industrial digitalization, operational technology (OT) cybersecurity, project and construction management, project procurement, detailed engineering and environmental services.

A portion of the purchase price for the transaction will be paid in WSP common shares to the sellers, including Fonds de solidarité FTQ, GCM Corpo’s largest shareholder.

“GCM Corpo is highly complementary to WSP and a strong strategic fit for our business. Canada’s energy and industrial sectors are evolving rapidly, driving demand for the scale, technology and expertise needed to support growth. Welcoming GCM Corpo will enhance our position across the energy and industrial value chain and expand our ability to partner with clients on some of the country’s most important and complex projects,” said Alexandre L’Heureux, President and Chief Executive Officer of WSP. “This transaction reflects our strong confidence in Canada’s long-term potential as a leader in the energy, industrial and mining sectors.”

“As we considered the next chapter for GCM Corpo, it became clear that joining WSP would allow us to accelerate the momentum we have created and pursue our ambitions from an even stronger position,” said Jonathan Clément, President of GCM Corpo. “WSP shares our roots, entrepreneurial spirit and commitment to technical excellence. We believe joining forces will allow us to build on the strengths and culture that have made GCM Corpo successful, while creating new opportunities for our people and delivering even greater value to our clients”.

“Supporting the long-term presence of corporate headquarters in Québec has long been a priority for the Fonds de solidarité FTQ. It was with this objective in mind that the Fonds and its Fonds régionaux invested in 2021 to support the evolution of GCM Corpo, an engineering consulting firm that has since experienced remarkable growth. I am delighted that GCM Corpo can now continue to grow and leverage its expertise within WSP, a flagship of Québec engineering,” said Janie C. Béïque, President and Chief Executive Officer of the Fonds de solidarité FTQ.

WSP has received conditional approval from the Toronto Stock Exchange (the “TSX”) with respect to the WSP common shares that will be issued as consideration in connection with the acquisition of GCM Corpo. Final approval of the listing of the WSP common shares is subject to the ordinary conditions of the TSX for transactions of this nature.

Completion of the transaction is subject to customary closing conditions, including regulatory approval. The transaction is expected to close in Q4 2026.

About WSP
WSP is one of the world’s leading engineering, science and infrastructure solutions firms, uniting its multidisciplinary expertise to shape communities to advance humanity. From local beginnings to a globe-spanning presence today, WSP operates in over 50 countries and employs approximately 83,000 professionals, known as Visioneers. Together, they pioneer solutions and deliver innovative projects in the transportation, infrastructure, environment, building, energy, water, mining, and metals sectors. WSP is publicly listed on the Toronto Stock Exchange (TSX:WSP).

About GCM Corpo
GCM Corpo is a group of six subsidiary companies specializing in engineering consulting, environmental services, construction management, industrial IT, technical design and recruitment. These subsidiaries, GCM Consultants, Volo Construction, Strana Talent, GCM Enviro Synergies, KuriosIT and HyperShell, bring together approximately 600 professionals in Québec, Western Canada and Atlantic Canada. They leverage their complementary capabilities to support industrial, energy and manufacturing clients across their projects. Through an integrated and agile approach, GCM Corpo delivers tailored, sustainable solutions that address clients’ specific needs while building close relationships founded on trust and professionalism.

For more information, please contact:

Alain Michaud Chief Financial Officer WSP Global Inc. alain.michaud@wsp.com (438) 843-7317

Forward-Looking Statements

Certain information contained in this press release is not based on historical or current facts and may constitute forward-looking statements or forward-looking information (collectively, “forward-looking statements”) under Canadian securities laws. Forward-looking statements may include estimates, plans, strategic ambitions, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not statements of fact, including references to assumptions.

Forward-looking statements in this press release may include, without limitation, statements about the proposed acquisition of GCM Corpo, the benefits, synergies and opportunities of such proposed acquisition; the expected closing date; expectations regarding complementarity and compatibility of GCM Corpo’s business with WSP’s existing business; the issuance of common shares as consideration for the proposed acquisition; other anticipated benefits of the potential acquisition and their expected impact on WSP’s delivery of its strategic plan and its long-term vision, future growth, results of operations, financial performance, business, prospects and opportunities, WSP’s business outlook, objectives, development, plans, integration, growth strategies and other strategic priorities, and WSP’s leadership position in its markets; and statements relating to WSP’s future growth, results of operations, financial performance, business, prospects and opportunities and other statements that are not historical facts.

Forward-looking statements are based on a number of assumptions believed by WSP to be reasonable as at the date hereof, including assumptions set out through this press release and including, without limitation, principal assumptions about the possibility that the proposed acquisition may not be completed at all due to a failure to obtain or satisfy the conditions (including the receipt of regulatory approval) to the closing; WSP’s ability to retain and attract new business, achieve synergies and maintain market position arising from successful integration plans relating to the proposed acquisition; WSP’s ability to complete the integration of GCM Corpo within anticipated time periods and at expected cost levels; WSP’s ability to attract and retain key employees in connection with the proposed acquisition; management’s expectations in relation to the future performance and economic conditions and other factors in relation to GCM Corpo; the realization of the expected strategic, financial and other benefits of the potential acquisition in the timeframe anticipated; as well as the assumptions underlying the 2025-2027 Global Strategic Action Plan issued on February 12, 2025 and the 2026 financial outlook set out in WSP’s press releases dated February 25, 2026, May 6, 2026 and August 5, 2026. If any of these assumptions prove to be inaccurate, WSP’s actual results could differ materially from those expressed or implied in forward-looking statements.

To the extent any forward-looking statement in this press release constitutes financial outlook or future-oriented financial information within the meaning of applicable Canadian securities laws, such information is intended to provide investors with information regarding WSP, including WSP’s assessment of future financial plans, and may not be appropriate for other purposes. Financial outlook (including assumptions about future events, including economic conditions and proposed courses of action, based on WSP’s assessment of the relevant information currently available), as with forward-looking statements generally, is based on current estimates, expectations and assumptions and is subject to inherent risks and uncertainties and other factors.

Although WSP believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. In evaluating these forward-looking statements, investors should specifically consider various risk factors, which, if realized, could cause WSP’s actual results or events to differ materially from those expressed or implied in forward-looking statements. Such risk factors include, but are not limited to, WSP’s inability to successfully integrate GCM Corpo’s business upon completion of the potential acquisition; the possible delay or failure to close the potential acquisition; the potential failure to realize anticipated benefits from the potential acquisition; the potential failure to obtain regulatory approvals and the final approval of the TSX in a timely manner, or at all; WSP’s or GCM Corpo’s businesses being adversely impacted during the pendency of the potential acquisition; change of control and other similar provisions and fees; risks relating to the post-acquisition business; the deterioration of our financial position or net cash position; our working capital requirements; our accounts receivable; our increased indebtedness and raising capital; the impairment of long-lived assets; our foreign currency exposure; our income taxes; as well as other risks detailed from time to time in reports filed by WSP with securities regulators or securities commissions or other documents that WSP makes public, which may cause actual results or events to differ materially from the results expressed or implied in any forward-looking statement.

These and other risk factors that could cause actual results or events to differ materially from our expectations expressed in, or implied by, our forward-looking statements are discussed in greater detail in section 20, “Risk Factors” of WSP’s MD&A for the fourth quarter and year ended December 31, 2025 and as supplemented by section 17, “Risk Factors” of WSP’s MD&A for the second quarter and the six-month period ended June 26, 2026, which are available on SEDAR+ at www.sedarplus.ca and which sections are incorporated herein by reference. Actual results and events may be significantly different from what we currently expect because of the risks associated with our business, industry and global economy and of the assumptions made in relation to these risks. As such, there can be no assurance that actual results will be consistent with forward-looking statements.

The forward-looking statements contained in this press release describe WSP’s expectations as of the date hereof and, accordingly, are subject to change after such date. Except as may be required under Canadian securities laws, WSP does not assume any obligation to publicly update or to revise any forward-looking statements made in this press release, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. WSP may also make oral forward-looking statements from time to time. WSP advises that the above paragraphs and the risk factors set forth in section 20, “Risk factors” of WSP’s MD&A for the fourth quarter and year ended December 31, 2025, and as supplemented by section 17, “Risk Factors” of WSP’s MD&A for the second quarter and the six-month period ended June 26, 2026, should be read for a description of certain factors that could cause the actual results of WSP to differ materially from the results expressed or implied in any oral forward-looking statements. Readers should not place undue reliance on forward-looking statements.

Second Non-Core Agency Sale Completed in September Under the Company’s Portfolio Monetization Strategy

$3.1 Million Secured Promissory Note Paid in Full on September 30, 2026

LAKEWOOD, NJ, Oct. 01, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“Reliance,” “EZRA” or the “Company”), an InsurTech company leveraging artificial intelligence, cloud computing and advanced technologies to transform the insurance agency/brokerage industry, today announced that it has completed the sale of substantially all of the assets of its Altruis Benefit Consulting (“Altruis”) subsidiary, a Michigan-based health insurance agency and benefits consulting business, for a cash purchase price of $8 million, plus an earnout of up to $1 million that may be earned over the three years following the closing. The $3.1 million secured promissory note delivered by the buyer at closing as part of the purchase price was paid in full on September 30, 2026.

Key Terms

• Cash purchase price plus earnout.  Of the $8 million cash purchase price, the Company has received approximately $7.5 million in cash, including payment in full of the buyer’s $3.1 million seller note, with the balance of $461,729 held by the buyer as customary indemnity and working capital holdbacks. In addition, the Company may earn up to $1 million in earnout payments over the three years following the closing, based on annual revenue growth of the acquired business.
• Continued execution of the strategy. The Altruis sale follows the Company’s sale of Southwestern Montana Insurance Center, which closed on September 11, 2026, and represents continued execution of the portfolio monetization strategy of non-core agencies.
• Transaction completed. The sale of Altruis closed on September 23, 2026.

Strategic Rationale

Reliance is engaged in the ongoing evaluation and selective monetization of non-core insurance agency assets to unlock value while accelerating its evolution into a technology-driven InsurTech company. By selectively monetizing established insurance operations, the Company is strengthening its balance sheet, improving its financial flexibility and redeploying capital into its proprietary AI platform, RELI Exchange and other strategic growth initiatives that management believes offer greater long-term growth opportunities. The Altruis sale provides the Company with an $8 million cash purchase price without the issuance of any shares of Reliance common stock.

“Completing the Altruis sale, following the Southwestern Montana transaction earlier this month, reflects the steady execution of our portfolio monetization strategy,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “With the buyer’s seller note now paid in full, the proceeds strengthen our balance sheet and give us more capacity to invest in our AI platform and the RELI Exchange network.”

“We will continue to evaluate opportunities across our agency portfolio,” Mr. Beyman continued. “Our focus is on allocating capital to the areas we believe offer the greatest long-term value for our shareholders.”

About Reliance Global Group, Inc.

Reliance Global Group, Inc. (Nasdaq: EZRA) is an InsurTech company leveraging artificial intelligence, cloud computing and advanced technologies to transform the insurance agency/brokerage industry. Through its growing portfolio of proprietary AI solutions and insurance operations, the Company is focused on enhancing operational efficiency, improving customer experiences and creating long-term shareholder value. Further information about the Company can be found at https://www.relianceglobalgroup.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical fact and may be identified by the use of words or expressions such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “target,” “project,” “potential,” or similar expressions, or by discussions of strategy, plans or intentions. Forward-looking statements in this press release include, without limitation, statements regarding: the amount, timing and payment of the earnout consideration, if any; the release of the indemnity and working capital holdbacks; any post-closing purchase price or working capital adjustments; the anticipated benefits of the completed sale of Altruis; the Company’s use of proceeds and the anticipated effects of the transaction on the Company’s cash position, capital structure and financial flexibility; the Company’s portfolio monetization strategy, including the monetization of mature insurance distribution assets and the redeployment of capital; and the continued development, deployment and potential commercialization of the Company’s proprietary artificial intelligence platform and its RELI Exchange InsurTech platform.

These statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties and other factors, many of which are beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may differ materially from those expressed or implied by these forward-looking statements.

Such risks and uncertainties include, without limitation: the risk that the earnout consideration is not earned or paid, in whole or in part; the risk of post-closing purchase price or working capital adjustments or indemnification claims, including against the holdback amounts; the loss of the revenue and operating cash flow historically contributed by Altruis and the resulting impact on the Company’s consolidated results of operations; the risk that net proceeds available to the Company are less than anticipated after transaction expenses and income taxes, including any limitation on the Company’s ability to utilize net operating loss carryforwards; the risk that the Company is unable to redeploy capital into initiatives that generate the anticipated returns; the Company’s ability to maintain compliance with the continued listing standards of The Nasdaq Capital Market; the Company’s ability to access additional capital on acceptable terms, or at all; the development, deployment, market acceptance and potential commercialization of the Company’s proprietary artificial intelligence technologies; competition, regulatory developments and other risks affecting the insurance brokerage and InsurTech industries; and general business, economic, market and geopolitical conditions. Additional information regarding these and other factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as amended, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission, copies of which are available free of charge at www.sec.gov.

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this press release speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: EZRA@crescendo-ir.com

To Nasdaq Copenhagen A/S                        1 October 2026
                                        Announcement no. 84/2026
                                        Inside information

Cash Flows

Pursuant to S. 24 of the Capital Markets Act, we hereby publish cash flow data on bonds issued by Jyske Realkredit. Please find the data in the attached file.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

For further information about format of data and content of the file we refer to the web site of Nasdaq at www.nasdaqomxnordic.com.

Questions may be addressed to Christian Bech-Ravn, Head of Investor Relations, tel. (+45) 89 89 92 25.

Yours sincerely

Jyske Realkredit

Please observe that the Danish version of this announcement prevails

www.jyskerealkredit.com

Attachments

• 84_YdlRk20261001JYK
• 84_YdlRk20261001JYK.xml

Suominen Corporation’s stock exchange release on October 1, 2026, at 3:15 p.m. (EEST)

Suominen Corporation (hereinafter the “Company”) has transferred without consideration a total of 324,000 of Company shares held by the Company as treasury shares to President and CEO Charles Héaulmé as a signing bonus on September 30, 2026.

As previously announced in the Company’s financial statements release on January 29, 2026, and the interim reports published on May 7, 2026, and on August 7, 2026, the President and CEO is entitled to a share-based signing bonus. The changes to the signing bonus as a result of the rights issue carried out by the Company earlier in the summer were announced in a stock exchange release published on September 16, 2026.

The decision on the directed share issue is based on the authorization granted to the Board of Directors by the Annual General Meeting of Shareholders on April 15, 2026, and as amended by the Extraordinary General Meeting on June 8, 2026. The resolutions of the Annual General Meeting were communicated in a stock exchange release on April 15, 2026, and the resolutions of the Extraordinary General Meeting on June 8, 2026.

After the transfer of shares, the Company holds a total of 94,263 treasury shares.

SUOMINEN CORPORATION                                                                              

For further information, please contact:

Kimmo Raunio, CFO, tel. +358 10 214 3053

Distribution:

Nasdaq Helsinki
Main media
www.suominen.fi

About Suominen Corporation

Suominen manufactures nonwovens as roll goods for wipes and other applications. Our vision is to be the frontrunner for nonwovens innovation and sustainability. The end products made of Suominen’s nonwovens are present in people’s daily life worldwide. Suominen’s net sales in 2025 were EUR 412.4 million and we have almost 700 professionals working in Europe and in the Americas. Suominen’s shares are listed on Nasdaq Helsinki. Read more at www.suominen.fi.

MUNCIE, Ind., Oct. 01, 2026 (GLOBE NEWSWIRE) — First Merchants Corporation (NASDAQ: FRME) today announced that CEO Mark Hardwick will retire at the end of the year after 29 years with the bank. The First Merchants Corporation Board of Directors announced that Mike Stewart, current First Merchants Bank President who has been with the bank for more than 18 years, will become President and CEO at the start of 2027.

“We wish Mark well and are grateful for his outstanding leadership through years of tremendous growth, including 18 acquisitions during his tenure,” said Jean Wojtowicz, Chair of the Board of Directors of First Merchants Corporation and First Merchants Bank. “We are extremely pleased to have a seasoned leader in Mike Stewart who has already proven ready to take First Merchants to the next level.”

“It’s been my great pleasure to serve as the CEO of this 133-year-old financial institution with nearly 300,000 clients, 126 locations in 3 states, and 2,200 employees who work every day to enhance the financial wellness of our communities and clients,” said Hardwick. “First Merchants is a company with a wonderful culture and endless opportunities. We have boldly stepped into those opportunities with a courageous expectant attitude.

“My faith is an important part of my life, and I want to dedicate more time to consultative faith-based leadership. My wife Cathy and I are excited about the next chapter in our life’s journey, and I am also incredibly proud of what we as a bank leadership team have accomplished together at First Merchants.”

Stewart is a familiar face to those inside and outside the Bank as an active leader in the community, currently serving on the Board of the Indianapolis Neighborhood Housing Partnership (INHP); Greater Indianapolis Progress Committee (GIPC), Indy Chamber, Indiana Chamber, Park Tudor Foundation and Second Presbyterian Foundation.

He also actively participates in Streets to Home Indy, Indiana Bankers Association, and American Heart Association. He previously served as Chairman of the Board of Bosma Industries and was a 20-year board member.

“We will continue our focus on organically growing in the communities we serve with renewed vigor,” said Stewart. “We have an excellent executive team, supported by locally based senior leaders across our footprint. Our strategy is to build on our Midwestern strength, growing through more and deeper relationships, smarter use of technology, and customer-centric products that expand our reach.

“My wife, Barb, and I have loved living in Indianapolis for 38 years and are excited for this next chapter of leading the bank to new levels of strength in Indy and in every market First Merchants is privileged to serve.”

About First Merchants Corporation  
With approximately $21 billion in assets, First Merchants Corporation (NASDAQ: FRME) is a registered bank holding company offering a full line of commercial and consumer banking services and wealth management services through First Merchants Bank and First Merchants Private Wealth Advisors in Indiana, Michigan, and Ohio. With more than 130 years of enhancing the financial wellness of the diverse communities it serves, First Merchants makes meaningful contributions through employee empowerment, philanthropy, charitable giving, financial wellness, and community home and business lending. The company has been honored for its attentive and knowledgeable service and culture by Forbes, Time Magazine, American Banker, and S&P Global Intelligence “Best Banks” awards. First Merchants attributes this recognition to a mission-driven team that is passionate about “helping you prosper” through attentiveness as its genuine and unique approach to customer service. To see how First Merchants is making a difference, go to https://www.firstmerchants.com/. 

Media Contact
Amy Hanna
Borshoff
317.695.6331
Amy.hanna@borshoff.biz

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/e0e6cdc7-46b0-4cde-9a81-e89962fb9658 

https://www.globenewswire.com/NewsRoom/AttachmentNg/4a12b290-5b9e-4c30-a8db-44c03879e7f9